Non-viral endostatin plasmid transfection of mesenchymal stem cells via collagen scaffolds

Sun, Xiaodan; Jeng, Lily; Bolliet, Catherine; Olsen, Bjørn R.; Spector, Myron

doi:10.1016/j.biomaterials.2008.10.020

Cited by 47 publications

(52 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of scaffolds as delivery systems for therapeutic genes is undergoing considerable investigation. [107][108][109] Gene therapy can be applied to the field of orthopedic regenerative medicine as a method for enhancing the expression of osteogenic and/or chondrogenic tissue inductive factors. 110,111 In this approach, cells seeded on an appropriate scaffold are transfected with plasmid DNA (pDNA; a circular loop of DNA coding) contained within the scaffold, thereby introducing specific DNA sequences into the cells which result in the expression of osteogenic/chondrogenic genes capable of enhancing healing and tissue formation.…”

Section: Collagen Scaffolds For Orthopedic Regenerative Medicinementioning

confidence: 99%

Collagen scaffolds for orthopedic regenerative medicine

Cunniffe

O’Brien

2011

JOM

View full text Add to dashboard Cite

How would you……describe the overall signifi cance of this paper?Collagen and collagen-based scaffolds offer distinct advantages when selected as biomaterials for use across a broad spectrum of regenerative medicine applications. However, relatively poor mechanical properties are often perceived to limit their usefulness for orthopedic applications. These problems can be overcome through enhanced crosslinking mechanisms or through the addition of a second, stiffer phase such as hydroxyapatite, thus allowing tailored composite scaffolds to meet specifi c tissue requirements. This overview will highlight the current state of the art of these scaffolds, and consider the exciting prospects and future directions of collagen-based technologies for orthopedic regenerative medicine.…describe this work to a materials science and engineering professional with no experience in your technical specialty?Disease, injury and trauma can cause damage and degeneration of tissues and organs in the human body, which requires treatments to facilitate their repair, replacement or regeneration. Tissue engineering aims to regenerate damaged tissues instead of replacing them, by implanting biological substitutes that restore, sustain, or improve tissue function. Tissue engineering relies considerably on the use of porous 3-D scaffolds to provide a suitable environment for the regeneration of tissues and organs. These scaffolds essentially provide a template for new tissue formation and are either seeded with cells prior to implantation or are implanted directly into the injured site and the body's own cells populate the construct to facilitate healing. This review article focuses on the use of collagen and collagen-based scaffolds for tissue engineering applications. Overview biomaterials for regenerative medicineCollagen and collagen-based scaffolds offer distinct advantages when selected as biomaterials for use across a broad spectrum of regenerative medicine applications. However, relatively poor mechanical properties are often perceived to limit their usefulness for orthopedic applications. These problems can be overcome through enhanced crosslinking mechanisms or through the addition of a second, stiffer phase such as hydroxyapatite, thus allowing tailored composite scaffolds to meet specifi c tissue requirements. This overview will highlight the current state of the art of these scaffolds, and consider the exciting prospects and future directions of collagen-based technologies for orthopedic regenerative medicine.

show abstract

Section: Collagen Scaffolds For Orthopedic Regenerative Medicinementioning

confidence: 99%

Collagen scaffolds for orthopedic regenerative medicine

Cunniffe

O’Brien

2011

JOM

View full text Add to dashboard Cite

show abstract

“…The scaffold allows for cells to attach, proliferate and form extracellular matrix (ECM). It should have an open and interconnected pore structure (with a porosity >90 %) that allows nutrients to penetrate into the scaffold in vitro and then vascularisation to occur in vivo [3][4][5][6][7]. It should also degrade at a suitable rate to match the rate of tissue formation.…”

Section: Introductionmentioning

confidence: 99%

Development and characterisation of a collagen nano-hydroxyapatite composite scaffold for bone tissue engineering

Cunniffe

Dickson

Partap

et al. 2009

J Mater Sci: Mater Med

173

146

View full text Add to dashboard Cite

“…69 Another approach for controlled gene delivery for tissue engineering purposes is loading biodegradable materials with DNA molecules. [71][72][73] Collagen-based scaffolds have been investigated as carriers for plasmid DNA. 71,73 For example, Capito and Spector have demonstrated that collagen-based scaffolds can serve as nonviral gene delivery vehicles for IGF-1, providing a locally sustained therapeutic level of IGF-1, which enhanced cartilage formation.…”

mentioning

confidence: 99%

“…[71][72][73] Collagen-based scaffolds have been investigated as carriers for plasmid DNA. 71,73 For example, Capito and Spector have demonstrated that collagen-based scaffolds can serve as nonviral gene delivery vehicles for IGF-1, providing a locally sustained therapeutic level of IGF-1, which enhanced cartilage formation. 71 Several gene therapy approaches have been established in preclinical animal models, namely a murine model of collagen-induced arthritis and an immunodeficient mouse model of RA.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Impact of Biological Agents and Tissue Engineering Approaches on the Treatment of Rheumatic Diseases

Silva

Martins

Teixeira³

et al. 2010

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

The treatment of rheumatic diseases has been the focus of many clinical studies aiming to achieve the best combination of drugs for symptom reduction. Although improved understanding of the pathophysiology of rheumatic diseases has led to the identification of effective therapeutic strategies, its cure remains unknown. Biological agents are a breakthrough in the treatment of these diseases. They proved to be more effective than the other conventional therapies in refractory inflammatory rheumatic diseases. Among them, tumor necrosis factor inhibitors are widely used, namely Etanercept, Infliximab, or Adalimumab, alone or in combination with disease-modifying antirheumatic drugs. Nevertheless, severe adverse effects have been detected in patients with history of recurrent infections, including cardiac failure or malignancy. Currently, most of the available therapies for rheumatic diseases do not have sufficient tissue specificity. Consequently, high drug doses must be administrated systemically, leading to adverse side effects associated with its possible toxicity. Drug delivery systems, by its targeted nature, are excellent solutions to overcome this problem. In this review, we will describe the state-of-the-art in clinical studies on the treatment of rheumatic diseases, emphasizing the use of biological agents and target drug delivery systems. Some alternative novel strategies of regenerative medicine and its implications for rheumatic diseases will also be discussed.

show abstract

Non-viral endostatin plasmid transfection of mesenchymal stem cells via collagen scaffolds

Cited by 47 publications

References 45 publications

Collagen scaffolds for orthopedic regenerative medicine

Collagen scaffolds for orthopedic regenerative medicine

Development and characterisation of a collagen nano-hydroxyapatite composite scaffold for bone tissue engineering

Impact of Biological Agents and Tissue Engineering Approaches on the Treatment of Rheumatic Diseases

Contact Info

Product

Resources

About